Mucosal Immunity
34.5K views | +24 today
Mucosal Immunity
The largest immune tissue in the body
Your new post is loading...
Your new post is loading...
Scooped by Gilbert C FAURE
January 18, 2021 1:37 PM
Scoop.it!

Gut CD4 + T cell phenotypes are a continuum molded by microbes, not by T H archetypes

Gut CD4 + T cell phenotypes are a continuum molded by microbes, not by T H archetypes | Mucosal Immunity | Scoop.it
Helper T cell subsets are characterized functionally by the cytokines they produce. Benoist and colleagues demonstrate that in vivo helper T cells do not manifest as discrete helper subsets but rather form a continuum shaped by microbial exposure.
No comment yet.
Rescooped by Gilbert C FAURE from Virus World
January 17, 2021 2:14 AM
Scoop.it!

Saliva Could Hold Clues to How Sick You Will Get from COVID-19

Saliva Could Hold Clues to How Sick You Will Get from COVID-19 | Mucosal Immunity | Scoop.it

Compared with nasal swabs, saliva tests may better reflect infection deep in the lungs.  To the known risk factors for developing severe COVID-19—age, male sex, or any of a series of underlying conditions—a new study adds one more: high levels of the virus in your saliva. Standard COVID-19 tests sample the nasal passage. But several new tests look for SARS-CoV-2, the pandemic coronavirus, in saliva, and the new work finds a striking correlation between high virus levels there and later hospitalization or death. If the results are confirmed, saliva tests could help doctors prioritize which patients in the early stages of the disease should receive medicines that drive down levels of the virus. “I thought it was pretty striking,” says Shane Crotty, a virologist at the La Jolla Institute for Immunology, who was not involved with the research. Crotty notes the results suggest virus levels in saliva reflect viral load deep in the lungs, where the disease does much of its damage in severe cases. “That is a fundamentally valuable insight,” Crotty says. The new work isn’t the first to link the body’s coronavirus load and disease outcome. Several research groups have found a correlation between high viral levels in the nasal passages at the time of a patient’s hospital admission and ultimate disease severity. But other groups have failed to find that same link. The standard test to detect SARS-CoV-2 samples nasal mucus using nasopharyngeal (NP) swabs. The procedure is unpleasant, but it is the customary way to sample respiratory pathogens. In recent months, however, several research groups have developed and received emergency use authorization from the U.S. Food and Drug Administration for tests detecting SARS-CoV-2 in saliva. Yale University researchers were among the first, and the university’s hospitals have been using both saliva and NP swab tests. In both cases, labs analyze the samples using quantitative reverse transcription polymerase chain reaction tests, which can detect genetic material from SARS-CoV-2 and quantify the number of viral particles in each milliliter of sample.

 

Researchers led by Akiko Iwasaki, an immunologist at Yale, compared viral loads in saliva and NP swabs from 154 patients and 109 people without the virus. They divided the patients into groups that had low, medium, and high viral loads as determined by both types of test. Then they compared those results with the severity of symptoms the patients developed later. They found that patients who developed severe disease, were hospitalized, or died were more likely to have had high virus loads in their saliva tests, but not in their NP swabs. Viral load in both saliva and nasal mucus declined over time in patients who recovered, but not in those who died. When Iwasaki and her colleagues reviewed patients’ electronic medical records for markers of disease in the blood, they found that high saliva viral loads correlated with high levels of immune signals such as cytokines and chemokines, nonspecific molecules that ramp up in response to viral infections and have been linked to tissue damage. People with more virus in their saliva also gradually lost certain cells that mount an immune response against viral targets, had lower levels of antibodies targeting the spike protein that the virus uses to enter cells, and were slower to develop the strong immune response needed to knock down the virus in cases where they recovered. The team’s results appeared on 10 January in a preprint that has not been peer reviewed.

 

Iwasaki and her colleagues argue that saliva may be a better predictor of disease outcome than nasal mucus because the latter comes from the upper respiratory tract, whereas severe disease is associated with damage deep in the lungs. “Saliva may better represent what is going on in the lower respiratory tract,” Iwasaki says, because cilia lining the respiratory tract naturally move mucus up from the lungs into the throat, where it mixes with saliva; coughs have the same effect. The results don’t have enough statistical power to reveal how much more likely a person with a high saliva viral load is to develop severe COVID-19, Iwasaki says. She is also eager for other groups to replicate the results, especially because efforts to link high NP swab viral loads with disease progression have had mixed results. If other research confirms the finding, “it would clear away a lot of the fog” around this disease, Crotty says. Monica Gandhi, an infectious disease expert at the University of California, San Francisco, adds that if saliva tests are predictive, they could help doctors identify patients to treat early with either antibodies to reduce viral load or steroids to tamp down overactive nonspecific immune responses. Saliva tests are cheaper and easier than NP tests, but much less widely available. So confirmation of the new results could bolster efforts to make saliva tests more readily available, says Sri Kosuri, CEO of Octant, Inc., a biotech company. “If this study happened in March, we’d be talking about whether we should be doing NP testing at all,” Kosuri says.

 

Preprint available in medRxiv  (Jan. 10, 2021):

https://doi.org/10.1101/2021.01.04.21249236 


Via Juan Lama
Gilbert C FAURE's insight:

of course

No comment yet.
Scooped by Gilbert C FAURE
January 14, 2021 2:27 PM
Scoop.it!

Distinct lung-homing receptor expression and activation profiles on NK cell and T cell subsets in COVID-19 and influenza | bioRxiv

bioRxiv - the preprint server for biology, operated by Cold Spring Harbor Laboratory, a research and educational institution
No comment yet.
Scooped by Gilbert C FAURE
January 13, 2021 10:25 AM
Scoop.it!

Can you spread Covid-19 if you get the vaccine? —

Can you spread Covid-19 if you get the vaccine? — | Mucosal Immunity | Scoop.it
Answering this question will take us one step closer to our new normal.
Gilbert C FAURE's insight:

MI is ridiculously complicated !!!

No comment yet.
Scooped by Gilbert C FAURE
January 12, 2021 12:47 PM
Scoop.it!

Breastfeeding promotes early neonatal regulatory T cell expansion and immune tolerance of non‐inherited maternal antigens - Wood - - Allergy

Breastfeeding promotes early neonatal regulatory T cell expansion and immune tolerance of non‐inherited maternal antigens - Wood - - Allergy | Mucosal Immunity | Scoop.it
Abstract Background Breastfeeding is associated with long‐term health benefits, such as a lower incidence of childhood infections, asthma, obesity and autoimmune disorders. However, little is known...
No comment yet.
Rescooped by Gilbert C FAURE from Hematology
January 11, 2021 1:45 PM
Scoop.it!

The distribution of cellular turnover in the human body

The distribution of cellular turnover in the human body | Mucosal Immunity | Scoop.it
We integrated ubiquity, mass and lifespan of all major cell types to achieve a comprehensive quantitative description of cellular turnover. We found a total cellular mass turnover of 80 ± 20 grams per day, dominated by blood cells and gut epithelial cells. In terms of cell numbers, close to 90% of the (0.33 ± 0.02) × 1012 cells per day turnover was blood cells. A comprehensive census of the dynamics of death and regeneration of cells and tissues provides an estimation of the distribution of cellular turnover in the human body.
No comment yet.
Scooped by Gilbert C FAURE
January 11, 2021 10:42 AM
Scoop.it!

Derivation of Airway Basal Stem Cells from Human Pluripotent Stem Cells - ScienceDirect

Derivation of Airway Basal Stem Cells from Human Pluripotent Stem Cells - ScienceDirect | Mucosal Immunity | Scoop.it
The derivation of tissue-specific stem cells from human induced pluripotent stem cells (iPSCs) would have broad reaching implications for regenerative…...
No comment yet.
Scooped by Gilbert C FAURE
January 10, 2021 12:59 PM
Scoop.it!

Regulatory B cells in respiratory health and diseases - Menon - - Immunological Reviews

Regulatory B cells in respiratory health and diseases - Menon - - Immunological Reviews | Mucosal Immunity | Scoop.it
Abstract B cells are critical mediators of humoral immune responses in the airways through antibody production, antigen presentation, and cytokine secretion. In addition, a subset of B cells, known...
No comment yet.
Scooped by Gilbert C FAURE
January 10, 2021 12:58 PM
Scoop.it!

Frontiers | Skin multi-omics-based interactome analysis: Integrating the tissue and mucus exuded layer for a comprehensive understanding of the teleost mucosa functionality as model of study. | Imm...

From a general structural perspective, a mucosal tissue is constituted by two main matrices: the tissue and the secreted mucus. Jointly, they fulfil a wide range of functions including the protection of the epithelial layer.
No comment yet.
Scooped by Gilbert C FAURE
January 9, 2021 4:20 AM
Scoop.it!

SARS-CoV-2 vaccines in development

SARS-CoV-2 vaccines in development | Mucosal Immunity | Scoop.it
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first reported in late 2019 in China and is the causative agent of the coronavirus disease 2019 (COVID-19) pandemic. To mitigate the effects of the virus on public health, the economy and society, a vaccine is urgently needed. Here I review the development of vaccines against SARS-CoV-2. Development was initiated when the genetic sequence of the virus became available in early January 2020, and has moved at an unprecedented speed: a phase I trial started in March 2020 and there are currently more than 180 vaccines at various stages of development. Data from phase I and phase II trials are already available for several vaccine candidates, and many have moved into phase III trials. The data available so far suggest that effective and safe vaccines might become available within months, rather than years. The development of vaccines against SARS-CoV-2 is reviewed, including an overview of the development process, the different types of vaccine candidate, and data from animal studies as well as phase I and II clinical trials in humans.
No comment yet.
Scooped by Gilbert C FAURE
January 8, 2021 2:50 PM
Scoop.it!

New Test Delivers Results in Minutes, Loss of Smell Common in Mild Cases, Entire UK Population To Be Home-Tested: COVID-19 Updates

New Test Delivers Results in Minutes, Loss of Smell Common in Mild Cases, Entire UK Population To Be Home-Tested: COVID-19 Updates | Mucosal Immunity | Scoop.it
Gilbert C FAURE's insight:

https://spectrumsolution.com/press-release-spectrum-in-countrywide-saliva-based-covid-19-testing-directive-for-uk/

No comment yet.
Rescooped by Gilbert C FAURE from Autoimmune diseases (Lupus, RA), Vaccines and Stem Cell Therapies Highlights
January 1, 2021 9:23 AM
Scoop.it!

Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease

Immunoglobulin A Targets a Unique Subset of the Microbiota in Inflammatory Bowel Disease | Mucosal Immunity | Scoop.it
Highlights
•
IgA-coated bacteria were evaluated in a large cohort of IBD patients using IgA-SEQ
•
IgA-SEQ identified distinct IBD-associated bacteria compared with the relative abundance
•
Anti-TNFα treated patients exhibited altered microbiota-specific IgA responses
•
IgA coating of Oscillospira was associated with a delay in time to surgery in IBD

Via Krishan Maggon
No comment yet.
Scooped by Gilbert C FAURE
December 28, 2020 8:01 AM
Scoop.it!

IJMS | Special Issue : Gut Microbiota and Immunity

IJMS | Special Issue : Gut Microbiota and Immunity | Mucosal Immunity | Scoop.it
International Journal of Molecular Sciences, an international, peer-reviewed Open Access journal.
No comment yet.
Scooped by Gilbert C FAURE
January 18, 2021 1:26 PM
Scoop.it!

Evolution of antibody immunity to SARS-CoV-2

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected 78 million individuals and is responsible for over 1.7 million deaths to date. Infection is associated with development of variable levels of antibodies with neutralizing activity that can protect against infection in animal models1,2. Antibody levels decrease with time, but the nature and quality of the memory B cells that would be called upon to produce antibodies upon re-infection has not been examined. Here we report on the humoral memory response in a cohort of 87 individuals assessed at 1.3 and 6.2 months after infection. We find that IgM, and IgG anti-SARS-CoV-2 spike protein receptor binding domain (RBD) antibody titres decrease significantly with IgA being less affected. Concurrently, neutralizing activity in plasma decreases by fivefold in pseudotype virus assays. In contrast, the number of RBD-specific memory B cells is unchanged. Memory B cells display clonal turnover after 6.2 months, and the antibodies they express have greater somatic hypermutation, increased potency and resistance to RBD mutations, indicative of continued evolution of the humoral response. Analysis of intestinal biopsies obtained from asymptomatic individuals 4 months after the onset of coronavirus disease-2019 (COVID-19), using immunofluorescence, or polymerase chain reaction, revealed persistence of SARS-CoV-2 nucleic acids and immunoreactivity in the small bowel of 7 out of 14 volunteers. We conclude that the memory B cell response to SARS-CoV-2 evolves between 1.3 and 6.2 months after infection in a manner that is consistent with antigen persistence.
No comment yet.
Scooped by Gilbert C FAURE
January 15, 2021 10:55 AM
Scoop.it!

Pathophysiology of Inflammatory Bowel Diseases | NEJM

Pathophysiology of Inflammatory Bowel Diseases | NEJM | Mucosal Immunity | Scoop.it
Pathophysiology of Inflammatory Bowel Diseases Research on IBDs has identified disrupted immune responses in the gastrointestinal mucosa and putative disruptions in the gut microbiome as causative ...
No comment yet.
Rescooped by Gilbert C FAURE from Immunology and Biotherapies
January 14, 2021 1:06 PM
Scoop.it!

Regulation of immune responses by the airway epithelial cell landscape

Regulation of immune responses by the airway epithelial cell landscape | Mucosal Immunity | Scoop.it
The community of cells lining our airways plays a collaborative role in the preservation of immune homeostasis in the lung and provides protection from the pathogens and pollutants in the air we breathe. In addition to its structural attributes that provide effective mucociliary clearance of the lower airspace, the airway epithelium is an immunologically active barrier surface that senses changes in the airway environment and interacts with resident and recruited immune cells. Single-cell RNA-sequencing is illuminating the cellular heterogeneity that exists in the airway wall and has identified novel cell populations with unique molecular signatures, trajectories of differentiation and diverse functions in health and disease. In this Review, we discuss how our view of the airway epithelial landscape has evolved with the advent of transcriptomic approaches to cellular phenotyping, with a focus on epithelial interactions with the local neuronal and immune systems. In this Review, Lloyd and Hewitt describe our contemporary understanding of the airway epithelial cell landscape. They highlight the new epithelial cell types that have been recently discovered and explain how epithelial cells interact with the immune and nervous systems to shape immunity in the airways.

Via Krishan Maggon
No comment yet.
Scooped by Gilbert C FAURE
January 12, 2021 2:32 PM
Scoop.it!

Expression of SARS‐CoV‐2 entry factors in human oral tissue - Sawa - - Journal of Anatomy

Expression of SARS‐CoV‐2 entry factors in human oral tissue - Sawa - - Journal of Anatomy | Mucosal Immunity | Scoop.it
Abstract The distribution of cells expressing SARS‐CoV‐2 entry factor angiotensin‐converting enzyme 2 (ACE2) and transmembrane serine protease 2 (TMPRSS2) in human oral tissues were tested. The inv...
No comment yet.
Scooped by Gilbert C FAURE
January 12, 2021 11:00 AM
Scoop.it!

IgA dominates the early neutralizing antibody response to SARS-CoV-2 | Science Translational Medicine

IgA dominates the early neutralizing antibody response to SARS-CoV-2 | Science Translational Medicine | Mucosal Immunity | Scoop.it
No comment yet.
Scooped by Gilbert C FAURE
January 11, 2021 1:04 PM
Scoop.it!

Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality | medRxiv

medRxiv - The Preprint Server for Health Sciences
No comment yet.
Scooped by Gilbert C FAURE
January 11, 2021 5:14 AM
Scoop.it!

Mucosal Immunity: Feces and Covid-19

Mucosal Immunity : Feces and Covid-19

 

Surprisingly, although detection of virus in feces has been reported since the beginning of pandemy in China, mainly in children, the number of published papers focusing on this topic remain very low (# 250 papers in one year of pandemy,  i.e 0,5% of Sars-Cov-2 published papers, more than 55000 according to PuBMed). Applications in diagnosis, epidemiology and follow-up of individual patients are almost inexistent. However, detection of viral material in effluents raised interest in published papers and are regularly reported in media.

 

This short opinion paper wants to address this issue and stimulate researchers and diagnostic companies developping clinical research projects in this direction.

 

If you consider results from search in PubMed , most papers (46%) originate from China some papers (10%) relate to animal coronavirus infection, and at least 15% report on sewage analysis. Papers reporting data on human diagnostic detection of virus in feces represent at most 50% of this collection.

 

Clinically,  the gastrointestinal tract is affected by COVID-19, gastrointestinal symptoms ranging from 7 to 60%, including diarrhea, nausea/vomiting, anorexia and abdominal pain.

 

Biologically, presence of viral RNA in stools is rarely tested, but positive up to 50%. Virus was detected later than in sputum and respiratory secretions up to several weeks after clinical symptoms. RNA material is detected with frequently dynamic intra-host variations during convalescence, and sometimes probably viable virus potentially infectious.

In the context, some chinese authors recommend including feces analysis particularly for discharge criteria

 

Epidemiological and environment data were established through detection of virus RNA in sewage and wastewaters and also in solid fraction. These tests appear efficient for detecting new waves of cases and are apparently widely in use in Europe.

Risk of transmission should be higher in developing countries where sanitation remains poor but data are lacking from such countries.

During the past few weeks, China has been also focusing on potential dangerosity of foreign frozen foods and reported detection of viral RNA on various imported food, from diverse countries. Infectivity has not been demonstrated,

 

As stated in a recent chinese paper, « … ignoring potential faecal transmission and the gastrointestinal involvement of SARS-CoV-2 may result in mistakes in attempts to control the pandemic. » Indeed, in recent control measures trying to limit contaminations in Beijing, ar least 3 fecal analysis became mandatory beginning of January.

 

 

Gilbert C FAURE's insight:

https://www.linkedin.com/pulse/mucosal-immunity-feces-covid-19-gilbert-faure/?published=t

No comment yet.
Scooped by Gilbert C FAURE
January 10, 2021 12:59 PM
Scoop.it!

Genomic profiling of intestinal T-cell receptor repertoires in inflammatory bowel disease

Genomic profiling of intestinal T-cell receptor repertoires in inflammatory bowel disease | Mucosal Immunity | Scoop.it
Growing evidence shows that inflammatory bowel disease (IBD) results from dysregulation of immune responses to gut microbes.T-cell receptors (TCRs) expressed on the T-cell surface play critical roles in discriminating pathogens from commensal intestinal microorganisms at the front line of the adapt...
No comment yet.
Scooped by Gilbert C FAURE
January 10, 2021 4:36 AM
Scoop.it!

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19

Assessing ACE2 expression patterns in lung tissues in the pathogenesis of COVID-19 | Mucosal Immunity | Scoop.it
It has been reported that SARS-CoV-2 may use ACE2 as a receptor to gain entry into human cells, in a way similar to that of SARS-CoV. Analyzing the distribution and expression level of ACE2 may therefore help reveal underlying mechanisms of viral susceptibility ...
No comment yet.
Scooped by Gilbert C FAURE
January 9, 2021 2:18 AM
Scoop.it!

T resident helper cells promote humoral responses in the lung | Science Immunology

T resident helper cells promote humoral responses in the lung | Science Immunology | Mucosal Immunity | Scoop.it
No comment yet.
Scooped by Gilbert C FAURE
January 7, 2021 8:11 AM
Scoop.it!

Microorganisms | Free Full-Text | Topography and Expansion Patterns at the Biofilm-Agar Interface in Bacillus subtilis Biofilms

Microorganisms | Free Full-Text | Topography and Expansion Patterns at the Biofilm-Agar Interface in Bacillus subtilis Biofilms | Mucosal Immunity | Scoop.it
Bacterial biofilms are complex microbial communities which are formed on various natural and synthetic surfaces. In contrast to bacteria in their planktonic form, biofilms are characterized by their relatively low susceptibility to anti-microbial treatments, in part due to limited diffusion...
No comment yet.
Scooped by Gilbert C FAURE
December 28, 2020 12:32 PM
Scoop.it!

Single-Cell Transcriptomics Reveal Immune Mechanisms of the Onset and Progression of IgA Nephropathy

Single-Cell Transcriptomics Reveal Immune Mechanisms of the Onset and Progression of IgA Nephropathy | Mucosal Immunity | Scoop.it
Zheng et al. produce in-depth, single-cell transcriptome data to demonstrate cell-type-specific
gene expression of IgAN. They provide insights into the potential mechanism of IgAN in which aberrant IgA deposition-related gene expression in mesangial cells trigger IgAN, inducing tubulointerstitial...
No comment yet.